Navigation Links
Insmed Announces Fourth Quarter and Full-Year 2010 Financial Results
Date:3/10/2011

ecovery from our IPLEX™ Expanded Access Program (EAP) in Europe, $0.5 million of IPLEX grant revenue which was recognized in the fourth quarter of 2009 and $0.1 million in lower royalties during the most recent period.  The reduction in the IPLEX cost recovery was due to the Company's decision in July 2009 to cease supplying the drug to new patients in order to preserve the remaining IPLEX inventory for patients currently receiving the drug.  The $0.5 million reduction in grant revenue related to a grant received in the fourth quarter of 2009 from the Muscular Dystrophy Association (MDA) for the previously completed IPLEX Phase 2 Myotonic Muscular Dystrophy trial.  The reduced royalty was due to the expiration of a TGF- beta royalty in 2010.

In the fourth quarter of 2010, the Company posted a net loss of $5.8 million, or $0.42 per share, as compared to a net profit of $2.3 million, or $0.18 per share, in the fourth quarter of 2009.  The $8.1 million variance arose from a $5.5 million increase in total expenses, the elimination of a $2.0 million tax refund which occurred in 2009 and a $1.2 million reduction in revenue.  These were partially offset by a $0.6 million improvement in investment income.

The $5.5 million increase in total expenses resulted from a $1.7 million increase in research and development expenses (R&D Expenses) and a $3.8 million increase in selling, general and administrative expenses (SG&A Expenses).  The higher R&D Expenses were due primarily to the addition of ARIKACE-related R&D Expenses in December 2010, while the increase in SG&A Expenses resulted from increased external finance, legal and consulting expenses related to the business combination, and the addition of ARIKACE-related support costs for December 2010.

The $2.0 million tax impact resulted from the utilization of Net Operating Losses in the fourth quarter of 2009, which reduced the amount of taxes paid o
'/>"/>

SOURCE Insmed Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Insmed to Host Second Quarter 2009 Conference Call
2. Insmed Announces Addition to the Russell 3000(R) Index
3. Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy
4. Insmed CEO Resigns Due to Health Concerns
5. Insmed Announces First Quarter 2009 Financial Results
6. Insmed Regains NASDAQ Compliance
7. Insmed to Host First Quarter 2009 Conference Call
8. Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
9. Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule
10. Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
11. Insmed to Host Fourth Quarter and Full-Year 2008 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014  Actavis plc (NYSE: ... company, and Rhythm, a biopharmaceutical company, today announced that ... Rhythm,s wholly owned subsidiary, Rhythm Health, Inc., which is ... treatment of diabetic gastroparesis and other GI functional disorders. ... 2 trial of relamorelin for the treatment of diabetic ...
(Date:10/22/2014)... WriteResult, LLC – a premier ... working with a team of researchers from Yale University’s ... Farming Collaborative to provide electronic questionnaire data collection through ... which started in May, aims to evaluate the impact ... exposure to and participation in urban agriculture to impact ...
(Date:10/22/2014)... Md. , Oct. 22, 2014   Synthetic ... developing novel pathogen-specific therapies for serious infections and diseases, ... has issued a Notice of Allowance for a composition ... its C. difficile program, SYN-004. This is ... SYN-004 in the U.S. and adds to the Company,s ...
(Date:10/20/2014)... The report “Pharmacy Automation Systems ... and Labeling Systems, Table-top Counters) by End-user (Inpatient ... & Trends to 2019” analyzes and studies the ... America, Europe, Asia-Pacific, and the Rest of the ... 30 figures spread through 300 pages and in-depth ...
Breaking Biology Technology:Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4
... mineral used in cat litter and other applications. The extraordinary ... mineral, despite its scarcity in the Earth,s crust: only a ... Madrid in Spain, the world,s biggest exporter of this material. ... was used to filter and purify wine, but our understanding ...
... The J. R. Simplot Company,s Plant Sciences business ... improving crops, leading to new, better and healthier ... Innate™ Technology is a patented plant ... genes to enhance desirable traits and to decrease ...
... Institute may help to explain why anticoagulant therapies have largely ... study was led by Deyan Luo, a postdoctoral fellow in ... of the blood clotting process, is critical for host defense ... sepsis in humans and experimental mice. The new data will ...
Cached Biology Technology:Cat litter to become an edible product? 2Trudeau Institute announces a discovery in the fight against sepsis 2
(Date:10/16/2014)... Northridge, Calif. (October 16, 2014) – Post-menopausal women ... effect on hormone levels or genital bleeding, after ... of an investigational fermented soy germ-based nutritional supplement ... according to a new peer-reviewed pilot study reported ... Society (NAMS) annual scientific meeting. , "These ...
(Date:10/15/2014)... our ability to assess the pandemic risk from strains ... we must not allow ourselves to become complacent that ... international consortium of scientists. , Influenza pandemics arise when ... yet to develop widespread immunity – spreads in the ... the past 100 years, the worst of which – ...
(Date:10/15/2014)... is spreading rapidly and to an unexpected extent. The ... past and the virus shows a new disease dynamic ... For this reason, the German National Academy of Sciences ... Engineering, and the Union of the German Academies of ... Ebola epidemic today. , In the statement the academies ...
Breaking Biology News(10 mins):S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5
... been amazed by the power of gecko feet, which let ... carrying nine pounds up a wall without slipping. Now, a ... of Massachusetts Amherst have discovered exactly how the gecko does ... hold 700 pounds on a smooth wall. Doctoral candidate ...
... single most common cause of congestive heart failure and sudden ... of people throughout Central and South America. But as global ... States and Europe as well. Chagas, which is ... T. cruzi , is the leading cause of death among ...
... world,s top conferences in human-computer interaction, TEI 2012, is ... world are coming to Kingston to present the latest ... the technology on display includes: a two-sided flexible TV ... yoga mats; a glove for deaf-blind people that translates ...
Cached Biology News:Inspired by gecko feet, UMass Amherst scientists invent super-adhesive material 2UGA animal vaccine may slow deadly spread of Chagas disease 2UGA animal vaccine may slow deadly spread of Chagas disease 3
... High signal and low background ,This ... several ten times higher than obtained with ... optimized for primary and secondary antibodies, which ... S/N ratio. , Wide versatility ,It ...
Mouse Anti-Human Killer Cell Immunoglobulin-like Receptor, Two Domains, Long Cytoplasmic Tail, 2 (KIR2DL2 (KIR2DL3 Monoclonal Antibody Family: Immunoglobulin Sub-Family: not assigned-Immunogl...
pH-dependent fluorescence; Maximum intensity observed in basic solutions....
Mouse anti human pro-Relaxin-2...
Biology Products: